Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Idenix Pharmaceuticals (UNKNOWN:IDIX.DL) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Idenix and see what CAPS investors are saying about the stock right now.

Idenix facts


Cambridge, Mass. (1998)

Market Cap

$649.7 million



Trailing-12-Month Revenue

$34.9 million


CEO Ronald Renaud
CFO Daniella Beckman

Trailing-12-Month Return on Equity



$205.3 million / $0


Bristol-Myers Squibb
Gilead Sciences
Vertex Pharmaceuticals

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 14% of the 234 members who have rated Idenix believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those bears, All-Star zzlangerhans, succinctly summed up the Idenix bear case for our community:

I find it difficult to value hepatitis C stocks but Idenix has risen sharply over the last three weeks without a clear precipitant that I can identify. The company announced plans for a phase II trial of all-oral combination of IDX719 and Janssen's simeprevir in their last earnings call, but this was fairly predictable after the announcement of the Janssen collaboration in January. Hepatitis C may still be an exciting and lucrative field but there's loads of competition and Idenix seems to be years behind in the development of all oral regimens.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.